This overview appeared in JAMA Dermatology.
All News
Wealth and Where you Live Influences Outcomes
Patients from wealthier European countries tend to start treatment with biologics earlier but also stop or switch treatment earlier. They also experience lower disease activity at treatment start than patients in middle- and low-income countries.
JAMA has published an overview of new considerations on Lyme disease, focusing on Diagnostics, Vaccines, and Prevention.
POETYK PsA-1 trial tested the disease modifying efficacy of deucravacitinib, a tyrosine kinase 2 (TYK2) inhibitor, in psoriatic arthritis (PsA) patients and was shown to be superior vs to placebo for clinical responses, patient-reported outcomes, and structural damage inhibition in PsA.
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Dactylitis, AKA the "sausage digit", is a hallmark of psoriatic arthritis (PsA), but as Possemato and colleagues point out, it is fundamentally a clinical sign, and not a diagnosis. This review article discusses the wider implications of dactylitis in rheumatology and medicine underscores the diagnostic and prognostic significance of this manifestation.
Beck et al has published a review of the VEXAS syndrome in The Lancet, focusing on the pathogenesis, spectrum, and treatment strategies.
New and updated clinical guidelines released today provide comprehensive, evidence-based recommendations for the management of axial spondyloarthritis (axSpA) for both adults and children.
B cell Targeting in SLE
Prospects are growing that an approved, off-the-shelf drug can rescue patients with certain ultra-refractory autoimmune diseases, a pair of new reports suggest.
It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.
Psoriatic arthritis develops in approximately 20 to 30 per cent of patients with psoriasis, yet predicting which patients will make the transition and when, has remained one of the most clinically challenging questions in rheumatology. A study presented at EULAR 2026 provides the most granular ultrasound characterisation yet of the journey from psoriasis, through subclinical disease, to early clinical PsA. The study identifies the specific imaging features that distinguish patients whose arthralgia is progressing toward arthritis from those who remain stable.
At EULAR 2026, Dr Nikolaos Kougkas presented data from a unique real-world cohort built within joint dermatology–rheumatology university centers, following 394 patients with psoriasis on bDMARDs for up to 17 years. We sat down with Dr Kougkas to unpack the methodology, challenge the results, and draw out the clinical implications for everyday practice.
